PledPharma awarded Nordic Star of the Year
September 10, 2014
PledPharma AB Company Announcement PledPharma awarded Nordic Star of the Year Stockholm, 2014-09-10 08:00 CEST (GLOBE NEWSWIRE) -- PledPharma, the Swedish pharmaceutical company that develops new therapies for life threatening diseases, has been acknowledged Nordic Star of the Year at the Nordic Life Science Days Conference held in Stockholm, Sweden, during September 8-9, 2014. PledPharma is the Swedish representative among the three companies that showcase the strong innovation of the Nordic Life Science industry. During this year’s edition of Nordic Life Science Days, PledPharma was rewarded for being a shining example of an innovative life science company. “PledPharma has an exciting clinical project platform that is based on a novel technology and targets significant medical needs. Step by step are they confidently moving towards their goal. Expect no less from a Nordic Star! ” About Nordic Stars Awards The Nordic Stars Awards was established in 2013 to reward companies that highlight the innovative Nordic life science community. Nordic Life Science Days Nordic Life Science Days is the Nordic region’s largest partnering conference for the global life science industry. The conference attracts leading decision-makers in the life science sector, including the bioengineering, pharmaceuticals and Med Tech segments, along with investors, research institutions, politicians and authorities. This year’s Nordic Life Science Days event is taking place in partnership with Oslo Cancer Cluster and Toulouse Cancer-Bio-Santé Cluster. For further information, please contact: Jacques Näsström, CEO +46 737 13 09 79 Jacques.nasstrom@pledpharma.se Michaela Gertz, CFO +46 709 26 17 75 Michaela.gertz@pledpharma.se About PledPharma PledPharma is a Swedish pharmaceutical company that develops new therapies for the treatment of life threatening diseases. The initial objective is to develop a drug, PledOx®, which reduces severe side-effects associated with chemotherapy. The current market for supportive cancer care is some USD 10 billion. PledPharma also evaluates an existing medicines possibility to reduce the damage that occurs on the heart muscle when patients suffer from acute myocardial infarction. In addition to these projects, the company is also evaluating opportunities of using our technology platform in additional areas where there is a significant unmet medical need. PledPharma has the potential to offer patients valuable and unique treatments for serious life-threatening diseases where there is an opportunity fast registration in the US through "breakthrough therapy" designation. This means that the company has the potential to offer shareholders a good return on their investment. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik Penser Bankaktiebolag is the Certified Adviser. For further information, please visit www.pledpharma.se
